



7th ACTC

Advances in Circulating Tumor Cells "Liquid Biopsy: From Bench to Bedside"



Makedonia Palace Hotel
Thessaloniki • Greece

September 24-27, 2025



hslb

ORGANIZER

- Evi Lianidou, University of Athens
- Hellenic Society of Liquid Biopsy

Under the Auspices of

EACR European Association
for Cancer Research



HELLENIC REPUBLIC
National and Kapodistrian
University of Athens
EST. 1837



IFCC
International Federation
of Clinical Chemistry
and Laboratory Medicine



ISLB
INTERNATIONAL SOCIETY
OF LIQUID BIOPSY



EORTC

www.actc2025.org



FINAL PROGRAM

Organizer



- Evi Lianidou, University of Athens
- Hellenic Society of Liquid Biopsy

Under the Auspices of



4

7th ACTC • Thessaloniki, Greece

Local Organizing Committee

Ioannis Boukovinas

MD, PhD, Head, Bioclinic Thessaloniki Medical Oncology Unit, Department of Medical Oncology, Thessaloniki, Greece

Galatea Kallergi

PhD, Assist. Professor, Laboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, Greece

Athina Markou

PhD, Assist. Professor, ACTC lab, Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Greece

Aliki Ntzifa

PhD, ACTC lab, Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Greece

Areti Strati

PhD, ACTC lab, Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Greece

International Scientific Committee

Valsamo Anagnostou

MD-PhD, Associate Professor, Medical Oncology, Leader, Precision Oncology Analytics, Director, Thoracic Oncology Biorepository, Co-director, Thoracic Oncology Precision Medicine Center of Excellence, Upper Aerodigestive Oncology Program, Co-leader, Molecular Tumor Board, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Johann de Bono

Professor, Head of the Division of Clinical Studies, The Institute for Cancer Research (ICR) and Royal Marsden, London, UK

Richard J. Cote

M.D. FRCPath, FCAP, Professor and Incoming Chair, Department of Pathology and Immunology, Pathologist-in-Chief, Barnes-Jewish Hospital, Washington University in St Louis, St Louis, USA

Massimo Cristofanilli

MD, FACP, Professor of Medicine, Chief, Breast Medical Oncology, Associate Director of Precision Medicine, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Scientific Director, the Englander Institute of Precision Medicine, Co-Leader, Meyer Cancer Center Management Team, Weill Cornell Medicine/New York-Presbyterian Hospital, Department of Medicine, Division of Hematology-Oncology, New York, USA

Caroline Dive

PhD, Director, Cancer Research UK National Biomarker Centre, The University of Manchester, UK

Ellen Heitzer

PhD, Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria

Dave Hoon

PhD, Director, Translational Molecular Medicine, SJCI PHS, Santa Monica, California, USA

Michail Ignatiadis

MD, PhD, Director, Breast Medical Oncology Clinic & Program, Medical Oncology Department, Institut Bordet, Associate Professor, Université Libre de Bruxelles, Chair, Breast Cancer Group, EORTC, Brussels, Belgium

Peter Kuhn

PhD, Dean's Professor of Biological Sciences and Professor of Medicine, Biomedical Engineering, Aerospace & Mechanical Engineering, and Urology, USC Michelson CSI-Cancer, Los Angeles, California, USA

Evi Lianidou

PhD, Professor of Analytical Chemistry – Clinical Chemistry, Analysis of Circulating Tumor Cells lab, Dept of Chemistry, University of Athens, Greece

International Scientific Committee

Mike Makrigiorgos

PhD, Professor and Director, Medical Physics and Biophysics, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA

Jean-Yves Pierga

MD, PhD, Professor of Medical Oncology, at the Institut Curie and Université Paris Descartes, Paris, France

Nikolas Stoecklein

MD, Professor, Experimental Surgical Oncology, Heinrich Heine University, Düsseldorf, Germany

Andreas Trumpp

PhD, Head, Division of Stem Cells and Cancer at the German Cancer Research Center (DKFZ), Heidelberg, Germany

Invited Speakers

Nicola Aceto

PhD, Institute of Molecular Health Sciences, ETH, Zurich, Switzerland

Julio Aguirre-Ghiso

PhD, Director, Institute for Cancer Dormancy and Tumor Microenvironment, Albert Einstein College of Medicine, New York, USA

Emmanuel Antonarakis

MD, Associate Director for Translational Research and Director of Genitourinary Oncology in HOT Division, University of Minnesota-Masonic Cancer Center, Minnesota, USA

Valsamo Anagnostou

MD-PhD, Associate Professor, Medical Oncology, Leader, Precision Oncology Analytics, Director, Thoracic Oncology Biorepository, Co-director, Thoracic Oncology Precision Medicine Center of Excellence, Upper Aerodigestive Oncology Program, Co-leader, Molecular Tumor Board, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Alberto Bardelli

Professor, Department of Oncology, University of Torino, and IFOM ETS - The AIRC Institute of Molecular Oncology, Milano, Italy

Thomas Carell

MD, Professor, Center for Nucleic Acid Therapies at the Department of Chemistry, Institute for Chemical Epigenetics, Ludwig-Maximilians-Universität München, München, Germany

Ryan Corcoran

MD, Associate Professor, Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA

Richard J. Cote

M.D. FRCPath, FCAP, Professor and Incoming Chair, Department of Pathology and Immunology, Pathologist-in-Chief, Barnes-Jewish Hospital, Washington University in St Louis, St Louis, USA

Massimo Cristofanilli

MD, FACP, Professor of Medicine, Chief, Breast Medical Oncology, Associate Director of Precision Medicine, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Scientific Director, the Englander Institute of Precision Medicine, Co-Leader, Meyer Cancer Center Management Team, Weill Cornell Medicine/New York-Presbyterian Hospital, Department of Medicine, Division of Hematology-Oncology, New York, USA

Johann de Bono

Professor, Head of the Division of Clinical Studies, The Institute for Cancer Research (ICR) and Royal Marsden, London, UK

Daniel De Carvalho

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Caroline Dive

PhD, Director, Cancer Research UK National Biomarker Centre, The University of Manchester, UK

September 24-27, 2025

General Information



Meeting Venue

Makedonia Palace Hotel, 2. M. Alexandrou Av., 546 40, Thessaloniki, Greece, Tel: +30 231 089 7197, Web: www.makedoniapalace.com



Official Language

The official language of the Meeting is English. No simultaneous interpretation will be provided.



Certificate of Attendance

All registered delegates who have attended the Meeting will receive an electronic Certificate after completing the delegates' survey, which will be sent via email after the event.



Conference Organizing Bureau

Erasmus Conference & Events S.A.
49 Chaldeias Str., 167 77, Elliniko, Greece
Call Centre: +30 210 7414700, E-mail: info@actc2025.org



Registration Desk

The registration desk is situated at the Makedonia Palace Hotel and will operate during the following dates and hours:

Tuesday, September 23 rd , 2025	19:00 - 21:00
Wednesday, September 24 th , 2025	08:00 - 18:30
Thursday, September 25 th , 2025	08:00 - 18:30
Friday, September 26 th , 2025	08:00 - 18:30
Saturday, September 27 th , 2025	08:30 - 12:30



Coffee breaks & Lunches

Coffee and lunch breaks are included in the registration fee.



Internet

Free Wi-Fi will be available in all meeting areas and guest rooms throughout the event.



Posters' Area

All participants are encouraged to visit the Poster area. Posters will be available throughout the meeting.

Poster Session 3 | CTCs and ctDNA clinical applications

- PP087 Liquid biopsy in molecular diagnostics and scientific research in Serbia – insights from the STEPUPRIORS and EXPAND-EV Horizon Europe projects**
Milena Cavic¹, Ana Djuric¹, Mladen Marinkovic^{2,3}, Aleksandra Stanojevic¹, Miodrag Vukovic¹, Lidija Filipovic⁴, Ana Damjanovic¹, Miljana Tanic¹, Vanja Stevanovic¹, Teodora Cato¹, Suzana Stojanovic-Rundic^{2,3}, Remond Fijneman⁵, Sergi Castellvi-Bel⁶, Ieronymos Zoidakis^{7,8}, Jelena Spasic⁹, Radmila Jankovic¹, Milica Popovic⁴
¹Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, ²Clinic for Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, ³Faculty of Medicine, University of Belgrade, Belgrade, Serbia, ⁴Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Belgrade, Serbia, ⁵Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁶Gastroenterology Department, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Clínic Barcelona, University of Barcelona, Barcelona, Spain, ⁷Department of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁸Department of Biology, National and Kapodistrian University of Athens, Athens, Greece, ⁹Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
- PP088 Prostate-specific membrane antigen expression in metastatic castration naïve prostate cancer patients**
 Eshwari Dathathri², Khrystany Isebia³, Tanja van Dijk³, Afroditi Nanou², Fikri Abali², Michiel Stevens², Ruchi Bansal², Leon Terstappen^{1,2,4}, Jaco Kraan³, Nick Beijer³, John Martens³, Danny Houtsma⁵, Paul Hamberg⁶, **Frank Coumans**⁴
¹Decisive Science, Amsterdam, The Netherlands, ²Department of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands, ³Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands, ⁴Department of General, Visceral and Pediatric Surgery, Heinrich-Heine University, University Hospital Düsseldorf, Düsseldorf, Germany, ⁵Department of Medical Oncology, Haga Hospital, Den Haag, The Netherlands, ⁶Department of Oncology, Franciscus Gasthuis & Vlietland Hospital, Schiedam, The Netherlands
- PP089 Circulating Melanoma Cells: Unveiling EMT and Invasiveness Through Molecular Profiling**
Maria Cristina Rapanotti¹, Elisa Cugini², Cosimo Di Raimondo³, Tara Mayte Suarez Viguria¹, Maria Giovanna Sciolli¹, Tonia Cenci¹, Lorena Vergili¹, Debora Coletta⁴, Silvia Anzellotti¹, Piero Rossi⁵, Elena Campione³, Amedeo Ferlosio¹, Anastasia De Luca⁶, Luca Bianchi³, Augusto Orlandi¹
¹Department of Anatomic Pathology, University of Rome "Tor Vergata", Rome, Italy, ²Department of Laboratory Medicine, University of Rome "Tor Vergata", Rome, Italy, ³Dermatology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy, ⁴Department of Oncology University of Rome "Tor Vergata", Rome, Italy, ⁵Surgery Division, Department of Surgery Sciences, University of Rome "Tor Vergata", Rome, Italy, ⁶Department of Biology, University of Rome "Tor Vergata", Rome, Italy
- PP090 The heterogeneity of Circulating Tumor Cells (CTCs) in the bloodstream of pancreatic cancer patients**
Chrysoula Tagari¹, Michael Gogolidis¹, Karolina Mangani¹, Argyro Roumeliotou¹, Anastasia Xagara², Constantinos Stathopoulos³, Sophia Karagiannis N⁴, Teresa Frisan⁵, Ioannis Pateras S⁶, Athanasios Kotsakis², Galatea Kallergi¹
¹Laboratory of Biochemistry and Metastatic Signaling, Division of Genetics, Cell and Developmental Biology, Department of Biology, University of Patras, Patra, Greece, ²Department of Medical Oncology, General University Hospital of Larissa, Larissa, Greece, ³Department of Biochemistry, School of Medicine, University of Patras, Patra, Greece, ⁴St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK, ⁵Department of Molecular Biology and Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden, ⁶Second Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Liquid biopsy in molecular diagnostics and scientific research in Serbia – insights from the STEPUPIORS and EXPAND-EV Horizon Europe projects

Milena Cavic¹, Ana Djuric¹, Mladen Marinkovic^{2,3}, Aleksandra Stanojevic¹, Miodrag Vukovic¹, Lidija Filipovic⁴, Ana Damjanovic¹, Miljana Tanic¹, Vanja Stevanovic¹, Teodora Cato¹, Suzana Stojanovic-Rundic^{2,3}, Remond Fijneman⁵, Sergi Castellvi-Bel⁶, Ieronymos Zoidakis^{7,8}, Jelena Spasic⁹, Radmila Jankovic¹, Milica Popovic⁴

¹Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

²Clinic for Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

³Faculty of Medicine, University of Belgrade, Belgrade, Serbia

⁴Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Belgrade, Serbia

⁵Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

⁶Gastroenterology Department, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Clínic Barcelona, University of Barcelona, Barcelona, Spain

⁷Department of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece

⁸Department of Biology, National and Kapodistrian University of Athens, Athens, Greece

⁹Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

Background: Liquid biopsy (LB) was introduced into routine clinical practice in Serbia in 2016 in the setting of lung cancer. Widening its implementation has proven financially and logistically challenging. National efforts employing clinicians and researchers, members of the STEPUPIORS and EXPAND-EV Horizon Europe projects and the ESMO-affiliated Association of Medical Oncologists of Serbia and EACR-affiliated Serbian Association for Cancer Research are expected to advance clinically significant LB implementation in Serbia.

Methods: At the Institute for Oncology and Radiology of Serbia (IORS), molecular diagnostics using for RAS/BRAF mutation testing for patients with metastatic colorectal cancer has been performed from tissue since 2008, and from liquid biopsy since 2024. A cohort of around 100 Serbian patients with rectal cancer treated with neoadjuvant chemoradiotherapy, was profiled using radiomics, proteomics and transcriptomics to yield useful data on new prognostic and predictive biomarkers in the locally advanced setting within the STEPUPIORS project. Blood draws were made in six clinically significant moments to correlate LB-derived data with clinical outcomes and stored in the first Serbian cancer biobank at IORS. Within the EXPAND-EV project, plasma and pleural effusion samples of patients with advanced non-small cell lung cancer were obtained for molecular diagnostics and isolation of extracellular vesicles (EVs) in search for new prognostic and predictive biomarkers.

Results: Within the pilot study of RAS/BRAF mutation testing from LB in the anti-EGFR therapy rechallenge setting, clinically significant data was obtained for 24 carefully selected patients. In lung cancer, LB testing from plasma and pleural effusion was successfully used for the detection of the resistance T790M *EGFR* mutation at progression on EGFR TKIs and at diagnosis when tissue biopsy was not available in around 300 cases. EVs were successfully isolated and characterized from pleural effusion samples yielding material for ongoing proteomics studies.

Conclusion: LB is well embedded in molecular diagnostics and scientific research in Serbia, but a clear national strategy is still lacking. Data from European and international collaborative scientific projects will be used as a basis for advancing clinically significant LB implementation in Serbia in the future, thus overcoming financial restrictions of the resource-limited national healthcare system.

Keywords: colorectal cancer, liquid biopsy, lung cancer, national policy.

Acknowledgements: This study was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (Agreement No. 451-03-136/2025-03/200043) and Horizon Europe Projects STEPUPIORS (Agreement No. 101079217) and EXPAND-EV (Agreement No. 101182851).